Nonsurgical Treatment of Peri-Implantitis Using Er:YAG Laser (2940 nm) and Photobiomodulation: A Randomized Controlled Clinical Trial. Clinical, Microbiological, and Patient-Reported Outcome Measures

OBJECTIVE: To evaluate the clinical, microbiological, and patient-reported outcome measures (PROMs) of Er:YAG laser and photobiomodulation (PBM) therapy compared with conventional mechanical debridement (MD) in the nonsurgical treatment of peri-implantitis. MATERIALS AND METHODS: were assessed at baseline and 3 months. Treatment success, defined as PD ≤ 5 mm, BoP at ≤ 1 site, and absence of suppuration, was assessed at 3 months. PROMs, including postoperative pain, analgesic use, anesthesia requirement, and satisfaction, were recorded during the first postoperative week. CLINICAL RELEVANCE: Er:YAG and PBM therapy may improve treatment success, enhance patient comfort, and support more predictable nonsurgical management of peri-implantitis.